Hybrid closed loop technology was associated with superior efficacy and safety outcomes relative to standard insulin therapy in T1D.

The Business Research Company Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

Lance Bass gave a health update to PEOPLE, sharing that his diabetes is “finally under control” and he’s been "experimenting" ...

Eli Lilly and Company's impressive Q4 earnings driven by tirzepatide's success, diverse portfolio, and promising pipeline.

Glucotrack has successfully completed its first in-human clinical study for the first real-time, continuous blood glucose monitor (CBGM) placed in the subclavian vein.

Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its ...

Gonzaga University and the UW School of Medicine hosted Irl Hirsch to lecture about the future of glucose monitoring.

An ad airing Super Bowl Sunday features “America’s deadliest epidemic,” obesity, and what can be done about it with the use ...

"Most men see us as their mother, not the co-parent in the home. We parent, they babysit. There's an unattainably high bar ...

CIRM awards US$ 4 mn grant to Entos Pharma to advance development of ENTLEP001, a durable and redosable genetic medicine to treat CGL: San Diego Friday, February 7, 2025, 15:00 Hr ...

Ride-hailing service Bolt says it is making rides safer and more comfortable for women with a new feature allowing female passengers to prioritise female drivers. This initiative also supports women ...

The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.